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Abstract
Background: Tripterygium wilfordii Hook F (TwHF), a medicinal plant that has been widely used in Chinese traditional
medicine, is proven effective for treating rheumatoid arthritis (RA), but its clinical efficacy and safety remain largely
undefined in comparison with conventional synthetic disease modifying anti-rheumatic drugs (DMARDs).
Methods: PubMed, Embase, Cochrane Library, CNKI, VIP, CBM, and WanFang Databases. Endpoints were ACR 20, 50,
and 70, and the number of withdrawals due to adverse events. Initially, traditional pairwise meta-analysis was
performed by using a random-effects model. Then, we performed network meta-analysis to compare different
therapies by using frequentist approach.
Results: A total of 22 trials (5255 participants) were identified. By direct comparison, TwHF was superior to sulphasalazine
according to ACR 20, 50 and 70. TwHF was superior to placebo according to ACR 20 and 50. By indirect comparisons,
TwHF was superior to methotrexate, leflunomide, sulphasalazine, tacrolimus, minocycline and placebo according to ACR
20. Ranking by the Surface under the Cumulative Ranking curve (SUCRA) values showed that TwHF had the greatest
probability for being the best treatment option according to ACR 20 (92.0 %) and ACR 50 (81.3 %), and the highest
probability to be in the second (57.8 %) ranking position after leflunomide (69.6 %) according to ACR 70. By both direct
and indirect comparisons, TwHF caused no more significant withdrawals than the placebo. The SUCRA values showed
that TwHF had the highest probability to rank sixth (26.7 %) after the placebo (45.6 %) in causing withdrawals.
Conclusions: Our data suggest that TwHF is effective and safe in the treatment of RA and has better clinical efficacy
in terms of ACR 20 and 50 than existing conventional synthetic DMARDs. In the absence of head-to-head treatment
comparison, the confidence in these estimates is low. Future comparative efficacy studies are warranted.
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Background
Rheumatoid arthritis (RA) is an autoimmune disease of
unknown etiology that is characterized by pain, stiffness,
and swelling of peripheral joints. If uncontrolled, it may
result in progressive joint destruction, deformity, disabil-
ity, and increased mortality. Given the chronic nature of
RA, it is important to obtain evidence of long-term success
of therapy with disease modifying anti-rheumatic drugs
(DMARDs). There are three major classes of DMARDs
including conventional synthetic, targeted synthetic
DMARDs, and biological agents [1]. These DMARDs
may prevent or reduce joint damage, and help to main-
tain regular structure and function of the joint. As first-
line treatment in RA, conventional synthetic DMARDs
are often used as monotherapy in the early course of
the illness [2].
Tripterygium wilfordii Hook F (TwHF), also known
as Lei Gong Teng or thunder god vine in traditional
Chinese medicine, has been used to treat RA [3] as a
DMARD for many years in China [4, 5]. There are ap-
proximately 380 metabolites been identified from ex-
tracts of TwHF. Three of the extracts dominate the
chemical profile and the medicinal chemistry of TwHF,
including triptolide, tripdiolide and triptonide [6]. The
extracts of TwHF have shown anti-inflammatory and
immunosuppressive activities both in vivo and in vitro
studies [7, 8]. A randomized double blind, placebo
controlled trial showed that RA patients who had
received six weeks of topical Tripterygium wilfordii
attained a markedly higher modified American College
of Rheumatology Criterion of 20 % (ACR 20) response
rate compared to those who had taken the placebo [9].
Another randomized, controlled trial (RCT) demon-
strated that RA patients who received 24 weeks of
TwHF extract achieved significantly greater ACR 20
response rate than those who were treated with sulfa-
salazine [10]. However, data from these studies and
others could not be pooled due to differing interven-
tions, comparisons and outcome measures [10–12].
Since head-to-head comparison studies are sparse,
traditional pairwise meta-analysis could not provide an
answer to which intervention is superior to others [13, 14].
Network meta-analysis is a recently developed method
that could deal with evidence from direct comparisons
(from studies directly comparing interventions) as well
as indirect comparisons (two treatments derived via a
common comparator) [15–17]. In this systematic re-
view and network meta-analysis, we aimed to evaluate
the efficacy and safety of TwHF compared with con-
ventional synthetic DMARDs with ACR 20, American
College of Rheumatology Criterion of 50 % (ACR 50),
and American College of Rheumatology Criterion of
70 % (ACR 70) as the primary outcomes and safety as
the secondary outcome.
Methods
Data sources and searches
Our study protocol was registered on PROSPERO
(CRD42014015179). We searched PubMed, EMBASE,
and the Cochrane Library. In addition, we searched
the Chinese databases, including the CNKI Database,
VIP, CBM, and WanFang Database. All the databases
were searched from their date of inception to the
latest issue (Jan, 2015).
Searches included a combination of free-text and
Medline Subject Headings (MeSH) terms for ‘disease
terms’ with ‘drug names’, and were limited to published
‘human’ RCTs. For the English databases, we used free
text terms, such as “Tripterygium wilfordii Hook F”,
methotrexate, leflunomide, sulphasalazine, hydroxy-
chloroquine, cyclosporine A, azathioprine, cyclophos-
phamide, mycophenolate mofetil, tacrolimus (FK506),
intramuscular gold, auranofin, minocycline, D-penicil-
lamin, chlorambucil, “rheumatoid arthritis”, and “ran-
domized controlled trials”. For the Chinese databases,
free texts were used, such as “lei gong teng” and “lei
feng shi guan jie yan (rheumatoid arthritis)”. A filter
for clinical trials was applied. To collect an adequate
number of trials, we also searched the reference
lists of relevant publications to identify additional
studies.
Study selection
Only RCTs comparing conventional synthetic DMARDs
as monotherapy were included. The full-text publica-
tions were assessed for inclusion according to the
following criteria: (1) the subjects took TwHF extract
alone or conventional synthetic DMARDs for at least
12 weeks; (2) the study was a RCT with a parallel or
crossover design; (3) the treatment was used as an active
therapeutic intervention; (4) the enrolled subjects were
diagnosed with RA according to the 1987 Guidelines of
the American Rheumatology Association [18] or the
2010 ACR/ European League against Rheumatism
(EULAR) Criteria [19]; (5) the clinical endpoints were
ACR 20, 50, and 70 [20], and the safety endpoint was
withdrawal due to drug-emergent adverse events. TwHF,
in this review, mainly refers to the tripterygium glycoside
tablet and tripterygium tablet, two root preparations of
TwHF that have shown therapeutic promise [21, 22].
Studies using TwHF-containing herbs or other herbal
extracts were excluded. The analyses of outcomes were
conducted on an intent-to-treat (ITT) basis, or modified
ITT (number actually receiving treatment at baseline) if
the number randomized to treatment was not reported.
The eligibility of studies for the inclusion criteria was
assessed independently by four reviewers (C-GL, LG,
XG, and BL).
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Data extraction and quality assessment
Two investigators (C-GL and XG) independently extracted
and entered the following information into a database:
study design, patient characteristics, interventions, compar-
isons, and outcomes. When relevant information on design
or outcomes was unclear, or when doubt existed about du-
plicate publications, we contacted the original authors for
clarifications. Two investigators (H-DZ and H-LW) inde-
pendently evaluated the methodological quality of eligible
trials by using the Cochrane Collaboration’s tool for asses-
sing risk of bias [23] (random sequence generation, alloca-
tion concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome data,
selective reporting, and other sources of bias). Disagree-
ment between the two authors was resolved by discussion.
When disagreement persisted, two other senior investiga-
tors (QJ and X-HF) were consulted to attain consensus.
Data synthesis and analysis
The primary outcome of this analysis was treatment re-
sponse in terms of ACR 20, 50, or 70 defined as a 20 %,
50 %, or 70 % improvement in tender and swollen joints
and the same level of improvement in three of the five fol-
lowing variables: patient and physician global assessment
of overall disease activity; patient evaluation of pain; a
score of physical disability; blood acute-phase reactants.
The secondary outcome for safety was withdrawal of pa-
tients due to drug-emergent adverse events.
Network meta-analysis
Results are reported as odds ratios (ORs) with 95 % confi-
dence intervals (CI) for all comparisons of interventions.
Initially, traditional pairwise meta-analysis was performed
by using a random-effects model. Then, we performed
network meta-analysis to compare different therapies
by using frequentist approach [24, 25]. We included
multi-arm trials in the analysis by breaking multi-arm
trial into separate two-arm trials. We employed a multi-
variate random-effects meta-analysis model for each out-
come separately, combining direct evidence for each
comparison [26, 27].
For each ‘loop’ of treatment comparisons from three
or more independent sources and for each outcome, we
computed the difference between estimates from direct
and indirect evidence on the log OR scale. Inconsistency
was defined as disagreement between direct and indirect
evidence with a 95 % CI excluding 0.
For each outcome, we estimated the probability that
which intervention was the best for each outcome, the
second best, and the third best and so on, from the rank
orderings of the treatments at each interaction. Rank 1 in-
dicated the highest efficacy and Rank 8 means lowest of a
treatment. These ranking probabilities were used to calcu-
late the Surface under the Cumulative Ranking curve
(SUCRA), which is expressed as percentage (100 % for the
best intervention and 0 % for the worst intervention and
approximately 50 % for equivalent interventions) [28]. The
detailed methods of network meta-analysis in the study
are presented as Appendix Information (Additional file 1).
Funnel plot and publication bias
The difference between the observed effect size and
comparison-specific summary effect for each study was
calculated. This variable was then regressed on the stand-
ard error (SE), thus adding a simple linear regression line
in the funnel plot. This method could help visually deter-
mine if there is a publication bias in the results between
small and large studies.
We performed traditional and network meta-analysis
by using Stata software (version 12.0, the StataCorp,
College Station, Texas, USA).
Results
The flow chart of studies considered for inclusion is shown
in Fig. 1. On the basis of the title and abstract, 94 publica-
tions were selected and analyzed in full-text versions.
Additional file 2: Figure S1A through D shows the network
of all treatment comparisons analyzed according to ACR
20, 50, 70 and withdrawal. Eventually, 22 publications were
included in the systematic review. All reviews followed the
methods in the Cochrane Handbook, including standard-
ized searches, inclusion criteria and outcomes.
Characteristics of included studies
We found 22 eligible studies from 22 publications,
which enrolled a total of 5255 patients and evaluated 6
different conventional synthetic DMARDs.
Additional file 3: Table S1 summarizes the clinical and
methodological characteristics as well as the main outcomes
of each trial. Of the 22 trials included, TwHF was studied in
3 trials. Combined sample size in the TwHF arms was 149.
The risk of bias assessments for the included trials is illus-
trated in Additional file 2: Figure S2 and Figure S3. Most of
the evidence was of moderate-to-good quality. All 22
RCTs mentioned the word “randomization”. Over half of
the studies did not report adequate information about
allocation sequence generation and allocation sequence
concealment. Unblinded designs were used in half of the
trials included.
Clinical efficacy
ACR 20 was reported in 22 trials (5255 participants)
(Additional file 3: Table S1), covering all the eight
interventions of interest (Table 1). Based on direct com-
parison alone, TwHF was statistically significantly superior
to sulphasalazine and placebo (OR from 3.81 to 36.77,
95 % CI excluded 1). Based on indirect comparisons
alone, TwHF was statistically significantly superior to
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Results of direct comparisons are listed in the lower-left triangle, and the estimation is calculated as the row-defining treatment compared with the column-
defining treatment. Results of network meta-analysis are listed in the upper-right triangle, and the estimation is calculated as the column-defining treatment
compared with the row-defining treatment
TwHF Tripterygium wilfordii Hook F, MTX methotrexate, LEF leflunomide, SSZ sulphasalazine, CsA cyclosporine, FK506 tacrolimus, MINO minocycline
Fig. 1 The flow chart of studies considered for inclusion
Wang et al. BMC Complementary and Alternative Medicine  (2016) 16:215 Page 4 of 8
methotrexate, leflunomide, sulphasalazine, FK506, minocy-
cline and placebo (estimated ORs ranged from 11.76 to
33.33, 95 % CI excluded 1). The ranking information for
all interventions by the SUCRA values is shown in Add-
itional file 2: Figure S4A and Table 2. According to the
ranking probabilities, TwHF had the greatest probability
(92.0 %) for being the best treatment option according
to ACR 20, followed by leflunomide (63.4 %) and
sulphasalazine (62.4 %) versus the placebo (6.6 %).
ACR 50 was reported in 13 trials (2590 participants),
covering seven interventions of interest (Additional file 3:
Table S2). Based on direct comparisons alone, TwHF was
statistically significantly superior to sulphasalazine and pla-
cebo (OR from 9.67 to 21.97, 95 % CI excluded 1). Based
on indirect comparisons alone, TwHF was statistically sig-
nificantly superior to placebo (OR 11.11, 95 % CI excluded
1). Additional file 2: Figure S4B and Table 2 show the
SUCRA values for all interventions. According to the rank-
ing probabilities, TwHF had the greatest probability (81.3 %)
to be the best treatment option according to ACR 50,
followed by leflunomide (67.3 %), methotrexate (61.1 %),
and cyclosporine A (50.2 %) versus the placebo (8.7 %).
ACR 70 was reported in 10 trials (2182 participants),
covering seven interventions of interest (Additional file 3:
Table S3). Based on direct comparisons alone, TwHF was
statistically significantly superior to sulphasalazine (OR 12,
95 % CI excluded 1). Based on indirect comparisons alone,
TwHF caused no more significant than other interven-
tions. Additional file 2: Figure S4C and Table 2 show the
ranking information for all interventions by the SUCRA
values. The treatment of TwHF showed the highest prob-
ability to be in the second (57.8 %) ranking position after
leflunomide (69.6 %) and followed by FK506 (54.5 %) and
cyclosporine A (51.0 %) versus the placebo (24.7 %).
Safety
The number of withdrawals was reported in 15 trials
(3928 participants), covering seven interventions of
interest (Table 3). Based on direct comparisons alone,
TwHF caused no more significant withdrawals than the
placebo (OR 0.37, 95 % CI included 1) while leflunomide,
and sulphasalazine led to more withdrawals due to adverse
events than the placebo (estimated ORs ranged from 3 to
3.32, 95 % CI excluded 1). Based on indirect comparisons
alone, TwHF caused no more significant withdrawals than
the placebo (OR 0.36, 95 % CI included 1) while lefluno-
mide, and sulphasalazine led to more withdrawals due to
adverse events than placebo (estimated ORs ranged from
1.92 to 3.33, 95 % CI excluded 1). The SUCRA values
presented in Additional file 2: Figure S4D and Table 2
show the ranking information for all interventions. Ac-
cording to this rank probability, TwHF had the highest
probability to be ranked at the sixth (26.7 %) after the pla-
cebo (45.6 %), while sulphasalazine had the greatest prob-
ability (88.8 %) for causing most withdrawals.
Evaluating and presenting assumptions
Inconsistency check
Statistical inconsistency between direct and indirect com-
parisons was generally low for 4 outcomes (Additional
file 2: Figures S5A through D). All loops were consist-
ent because the 95 % CIs included 0 according to the
forest plots, indicating that the direct estimation of the
summary effect does not differentiate from the indirect
estimation. The summary estimations of the network
meta- analysis are relatively robust.
Estimated summary effects
We presented the mean effect sizes for the network esti-
mates along with their CI and predictive intervals (PrI),
all based on an assumption of a common heterogeneity
variance (Additional file 2: Figures S6A through D). The
plot indicates that TwHF appear more effective than
methotrexate, leflunomide, FK506, and minocycline in
ACR 20. The CI for TwHF vs sulphasalazine potentially
change the interpretation of the findings compared with
the PrI for ACR 20, since they extend across the line of
OR = 1 when the PrI does not.
Funnel plot and publication bias
Funnel plots for ACR 20, 50, 70 and withdrawals are shown
in Additional file 2: Figures S7A through D. Scatters in the
4 funnel plots were almost symmetrical visually, indicating
that the publication bias in the results of these 4 outcomes
between small and large studies was relatively low.
Discussion
Various extracts of HwHF has been widely used in China
for hundreds of years for various symptoms. The chloro-
form- methanol extract of the roots of TwHF has been
investigated as a potential treatment for autoimmune
diseases [12, 29–31]. Over the past 30 years, extracts of
Table 2 Ranking probability of DMARDs
Treatment ACR20 ACR50 ACR70 Withdrawal
SUCRA Rank SUCRA Rank SUCRA Rank SUCRA Rank
TwHF 0.920 1 0.813 1 0.578 2 0.267 6
MTX 0.418 6 0.611 3 0.454 6 0.158 7
LEF 0.634 2 0.673 2 0.696 1 0.758 2
SSZ 0.624 3 0.444 5 0.470 5 0.888 1
CsA 0.526 4 0.502 4 0.510 4 0.483 4
FK506 0.453 5 0.369 6 0.545 3 0.489 3
MINO 0.359 7 – – – – – –
Placebo 0.066 8 0.087 7 0.247 7 0.456 5
TwHF Tripterygium wilfordii Hook F, MTX methotrexate, LEF leflunomide, SSZ
sulphasalazine, CsA cyclosporine, FK506 tacrolimus, MINO minocycline, SUCRA
surface under the Cumulative Ranking curve
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TwHF have become a standard therapy for rheumatoid
arthritis in China. Recently, extracts of TwHF have been
tested in the West and shown good efficacy [10, 32]. The
results of the current study showed that TwHF is effective
for treating active RA patients and is superior to placebo
and sulphasalazine according to ACR 20, 50, and 70.
TwHF is superior to conventional synthetic DMARDs such
as methotrexate, leflunomide, sulphasalazine, FK506 and
minocycline in clinical efficacy by ACR 20. Ranking by the
SUCRA values showed that TwHF had the greatest prob-
ability for being the best treatment option according to
ACR 20 and ACR 50, and the highest probability to be in
the second ranking position after leflunomide according
to ACR 70. More importantly, the result of the current
analysis found that TwHF is safe, causing no more
drug-emergent withdrawals than the placebo. Our find-
ings suggest that this Chinese herbal remedy is both
effective and safe in treating active RA, offering RA
patients a potentially effective and safe alternative to
conventional synthetic DMARDs whose efficacies are
hampered by untoward effects.
Consistent with our findings, a recent systemic review
also found that TwHF could be as effective as synthetic
DMARDs in the treatment of RA [33]. The same study
showed that the methodological quality of the studies in-
cluded in their study was generally low and the approach
the authors used cannot integrate all the evidence from
several comparators. Network meta-analysis combines
both direct and indirect evidence for multiple treatments
to estimate interrelations across all treatments. To the
best of our knowledge, our study represents the first
employment of network meta-analysis for comparing dif-
ferent conventional synthetic DMARDs in treating RA.
Using this approach, we were able to combine simultan-
eously all relevant evidence on conventional synthetic
DMARDs in treating RA patients, even in the absence of
direct comparative evidence for some treatment pairs,
encompassing four efficacy and safety outcomes.
Since more evidence of direct active comparisons is re-
ported, our network meta-analysis provides a useful and
complete picture for the propensity of anti-rheumatic
treatment. This statistical technique not only includes the
results of direct comparisons but also incorporates indir-
ect comparisons, particularly for TwHF versus lefluno-
mide, cyclosporine A, FK506, and minocycline, which
have been rarely compared in head to head trials. Based
on the data from 22 trials including 5255 patients ran-
domly assigned to eight different intervention regimes for
RA, we found substantial uncertainty about the relative
efficacy and safety of different interventions in respect of
the studied outcomes. As there were differences in treat-
ment efficacy and safety among those conventional syn-
thetic DMARDs, we also reported the probabilities of
ranking for these treatments, providing additional evi-
dence for the comparative efficacy of these conventional
synthetic DMARDs.
Our findings have several limitations. Firstly, trials inves-
tigating combination therapies were excluded in our study.
Although combination therapy is common in practice, the
large number of possible therapy combinations and scar-
city of trials comparing these treatments prompted us to
restrict our analysis to monotherapies for RA. Secondly,
variations of drug ingredients or doses may contribute to
variations in study outcomes. However, treating different
doses of the same drug or different drug ingredients as dif-
ferent treatment regiments would not be feasible owing to
insufficient patient numbers and events of forming a well-
connected network, so we only evaluated treatment effects
and safety of major drug classes. Thirdly, most included
studies did not mention the details of randomization
and concealed allocation, and some of them were of
small sample size. Due to the high risk of bias in these
studies, the results of our network meta-analysis might
be biased. Finally, as our review aimed to include only
English and Chinese full-length publications published
in peer-reviewed journals, there is a potential for publi-
cation bias.
Conclusions
Our network meta-analysis, for the first time, provides a
useful and complete picture of the associations between
TwHF, conventional synthetic DMARDs and placebo
Table 3 Odds ratio (95 % CI) by direct comparison (left lower part) and network meta- analysis (right upper part) based on safety
TwHF 1.21 (0.10–14.26) 0.19 (0.02–2.07) 0.11 (0.01–1.36) 0.66 (0.00–1.64e+28) 0.35 (0.03–3.74) 0.36 (0.04–3.85)
0.32 (0.03–3.19) MTX 0.16 (0.06–0.40) 0.09 (0.03–0.31) 0.55 (0.00–1.31e+28) 0.29 (0.11–0.73) 0.30 (0.14–0.68)
– 0.74 (0.49–1.10) LEF 0.58 (0.20–1.66) 3.48 (0.00–8.25e+28) 1.82 (0.93–3.54) 1.92 (1.18–3.13)
0.39 (0.16–1.01) 0.71 (0.40–1.25) 0.93 (0.51–1.36) SSZ 6.02 (0.00–1.43e+29) 3.15 (1.11–8.91) 3.33 (1.29–8.33)
– – 2.06 (0.35–12.06) – CsA 0.52 (0.00–1.27e+33) 0.55 (0.00–100.0)
– – – – – FK506 1.05 (0.67–1.67)
0.37 (0.01–9.98) 0.30 (0.14–0.68) 3.00 (1.87–4.83) 3.32 (1.30–8.45) – 1.03 (0.65–1.61) Placebo
Results of direct comparisons are listed in the lower-left triangle, and the estimation is calculated as the row-defining treatment compared with the column-defining
treatment. Results of network meta-analysis are listed in the upper-right triangle, and the estimation is calculated as the column-defining treatment compared with the
row-defining treatment
TwHF Tripterygium wilfordii Hook F, MTX methotrexate, LEF leflunomide, SSZ sulphasalazine, CsA cyclosporine, FK506 tacrolimus, MINO minocycline
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according to ACR 20, 50, 70 and safety. We found the
efficacy of TwHF was statistically significantly superior
to placebo according to ACR 20 and 50. TwHF was
statistically significantly superior to sulphasalazine ac-
cording to ACR 20, 50 and 70. Clinically important in-
formation from high-quality randomized trials is still
needed for decision-making regarding primary treatment
options for RA using TwHF. More trial evidence is re-
quired to reduce uncertainty. TwHF may be used as the
first line DMARDs agent in the treatment of RA. Network
meta-analysis may be useful to optimize the power of evi-
dence studies once data from new randomized controlled
studies in this field are published in the future.
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